Imbria Pharmaceuticals is a clinical-stage company transforming the treatment of cardiovascular disease by targeting cardiac energy metabolism
Imbria Pharmaceuticals is a clinical-stage company transforming the treatment of cardiovascular disease by targeting cardiac energy metabolism. The company’s focus is ninerafaxstat, a differentiated, first-in-class cardiovascular therapy.